Highlights Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Real-time Estimate Cboe BZX Other stock markets 02:24:42 2024-05-01 pm EDT			5-day change	1st Jan Change
7.26 ^USD	+1.82%		-0.69%	+7.11%

Mar. 18	Fulcrum Therapeutics Appoints Patrick Horn as Chief Medical Officer	MT
Mar. 18	Fulcrum Therapeutics, Inc. Announces Executive Changes	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 27	CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 27	CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Fulcrum Therapeutics Announces Lifting of Clinical Hold on Potential Sickle-Cell Disease Treatment	23-08-22	MT
Fda Lifts Clinical Hold on Fulcrum Therapeutics' Ftx-6058 for Sickle Cell Disease	23-08-22	CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Fulcrum Therapeutics, Inc. Appoints Alan A. Musso as Chief Financial Officer, Effective August 7, 2023	23-08-03	CI
Fulcrum Therapeutics Enters Exclusive License Agreement With CAMP4 Therapeutics to Advance Rare Blood Disorder Therapy	23-07-10	MT
Fulcrum Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Fulcrum Therapeutics Q4 Loss Narrows, Revenue Falls	23-03-09	MT
FULCRUM THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-03-09	AQ
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-09	CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2022	23-03-09	CI
Fulcrum Therapeutics Says FDA Places Hold on Investigational New Drug Application for FTX-6058; Shares Plunge	23-02-24	MT
Fulcrum Therapeutics, Inc. Announces Clinical Hold on FTX-6058 in Sickle Cell Disease	23-02-24	CI
Fulcrum Therapeutics CEO Bryan Stuart Steps Down, Robert Gould Named Interim CEO	23-01-04	MT
Fulcrum Therapeutics : Corporate Overview Presentation- January 2023	23-01-04	PU
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-08	CI
Fulcrum Therapeutics to Present New Data from the Open Label Extension of Phase 2 Redux4 Study	22-10-12	CI
Fulcrum Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Fulcrum Therapeutics, Inc.

Equities

FULC

US3596161097

Highlights

Filters